Ann: IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022, page-24

Hi Kluck,

I’m over the moon about CF33 progressing & in fact all the current trials. With new technology, there is always a risk, but backed up with all the pre-clinical data, an educated risk.

As for not being price sensitive, the study is ongoing & the market already is aware that Check-Vacc is in Cohort 2 dosing as per the prior ASX ANN.

Don’t sweat that stuff Kluck, because the information that comes out in the 2 posters, well that will be ‘price sensitive’ and meaningful to investors. It’s a journey…
we don’t need to make it harder on ourselves, or being looking elsewhere & thinking why haven’t IMU gone up on this news?

Many things don’t make a lot of sense at times, until you look back in hindsight.

GLTAH